Agilent Array Q3 Sales Rise 20 Percent Amid Decline in Bio-Analytical Revenue

Agilent said it saw "strong adoption" of its SurePrint comparative genomic hybridization arrays during the quarter.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.